Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2510116 | 0.74 | NR1H2 (0.53) | LMNASMN1; SMN2NR1H2HDAC6 | |
| SCHEMBL217306 | 0.73 | DRD2 (0.48) | — | |
| SCHEMBL7469070 | 0.71 | ESR1 (0.51) | NOTUMHDAC6 | |
| SCHEMBL5727021 | 0.70 | HTR1A (0.35) | — | |
| SCHEMBL22502088 | 0.69 | LMNA (0.36) | LMNASMN1; SMN2 | |
| SCHEMBL6962545 | 0.69 | MEN1 (0.41) | LMNARIPK1HDAC6 | |
| SCHEMBL8013063 | 0.69 | NOTUM (0.63) | LMNASMN1; SMN2NOTUM | |
| SCHEMBL3486703 | 0.69 | NOTUM (0.63) | LMNASMN1; SMN2NOTUM | |
| SCHEMBL952312 | 0.69 | ESR2 (0.62) | LMNASMN1; SMN2NR1H2 | |
| SCHEMBL697852 | 0.69 | KMT2A (0.41) | SMN1; SMN2NOTUMHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168966-B1 | BICYCLOANILINE DERIVATIVE | MSD KK (JP) | 2016-09-28 | — | — | EP | disclosed |
| US-8436004-B2 | Bicycloaniline derivative | MSD K.K. (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20110135601-A1 | BICYCLOANILINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. | 2011-06-09 | — | — | US | disclosed |
| EP-2168966-A1 | BICYCLOANILINE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135601-A1 | BICYCLOANILINE DERIVATIVE | WEE1, WEE2, CCNK | LMNA 2057/4885SMN1; SMN2 4185/4885NR1H2 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.